AtriCure
Manufacturer of medical technologies for atrial fibrillation treatment.
Company facts
- Founded
- 2000
- Employees
- 1,350
- Headquarters
- United States
- CEO
- Michael H. Carrel
- Type
- Public
- Listed
- NASDAQ: ATRC
About
At AtriCure, our mission is deeply rooted in healing the lives of patients affected by atrial fibrillation (Afib) and post-operative pain. We understand that our customers—electrophysiologists and cardiothoracic surgeons—face complex challenges in treating these conditions, which is why we are dedicated to providing best-in-class surgical solutions. Our commitment to 'Patients, People, and Partners' drives every innovation we bring to market, ensuring that we not only meet but exceed the standards of care required to improve patient outcomes globally. We have established ourselves as a leader in the medical device industry by developing pioneering technologies such as the Isolator Synergy Ablation System, the first FDA-approved device for the treatment of persistent Afib, and the AtriClip Left Atrial Appendage Exclusion System, the most widely sold LAA management device in the world. Beyond cardiac rhythm management, we are also transforming pain management with our cryoICE cryoSPHERE probes, offering patients relief in cardiac and thoracic procedures. By investing heavily in clinical science, education, and continuous innovation, we empower healthcare professionals to treat even the most difficult cases with confidence and precision.